Mini-review: new therapeutic options in hypoparathyroidism

Endocrine. 2012 Jun;41(3):410-4. doi: 10.1007/s12020-012-9618-y. Epub 2012 Feb 7.

Abstract

Hypoparathyroidism is a disorder characterized by hypocalcemia and low or absent parathyroid hormone (PTH). While standard treatment of hypoparathyroidism consists of oral calcium and vitamin D supplementation, maintaining serum calcium levels can be a challenge, and concerns exist regarding hypercalciuria and ectopic calcifications that can be associated with such treatment. Hypoparathyroidism is the only classic endocrine deficiency disease for which the missing hormone, PTH, is not yet an approved treatment. This mini-review focuses on the use of PTH in the treatment of hypoparathyroidism. There are two available formulations of PTH: teriparatide [human PTH(1-34)] and the full-length molecule, PTH(1-84). Both PTH(1-34) and PTH(1-84) lower supplemental vitamin D requirements and increase markers of bone turnover. Densitometric and histomorphometric studies in some subjects treated with PTH(1-84) demonstrate improvement in abnormal bone-remodeling dynamics and return of bone metabolism toward normal euparathyroid levels. Further detailed examination of skeletal features following therapy with the different treatment regimens and data regarding the effect of PTH on quality of life measures are under active investigation.

Publication types

  • Review

MeSH terms

  • Bone Density
  • Bone Density Conservation Agents / therapeutic use
  • Bone Remodeling
  • Hormone Replacement Therapy
  • Humans
  • Hypoparathyroidism / diagnosis
  • Hypoparathyroidism / diet therapy
  • Hypoparathyroidism / drug therapy*
  • Hypoparathyroidism / physiopathology
  • Parathyroid Hormone / therapeutic use
  • Peptide Fragments / therapeutic use
  • Recombinant Proteins / therapeutic use
  • Teriparatide / therapeutic use

Substances

  • Bone Density Conservation Agents
  • PTH protein, human
  • Parathyroid Hormone
  • Peptide Fragments
  • Recombinant Proteins
  • Teriparatide